FDA
approves Sa**fi/Regeneron cholesterol drug with limits
WASHINGTON (Reuters) - The U.S. Food and
drug Administration approved a potent new cholesterol-lowering
drug from Sa**fi SA and Regeneron Pharmaceuticals Inc on Friday but limited its approved use to patients
with a hereditary form of the condition and those
with cardiovascular disease.
